| Old Articles: <Older 7621-7630 Newer> |
|---|
 |
Pharmaceutical Executive
July 1, 2011
Al Topin |
10 Emergency Brand Building Questions Here are 10 questions that should drive your brand-building marketing program.   |
Pharmaceutical Executive
July 1, 2011 |
How to Prevent a Facebook Faux Pas Here are a few 'Like' and 'Dislike' practices that companies should consider, prior to Facebook's great enabling. |
Pharmaceutical Executive
July 1, 2011 |
Holy Surge of Enthusiasm! While Europe's EFPIA preaches about embracing change, much remains to be done to prove the adjustment in philosophy. |
Pharmaceutical Executive
July 1, 2011
Cabacungan & Clark |
New Ways to Gain New Brand Insights If you can learn to understand patient and physician behavior, you are well on your way to strengthening the position of your product. |
The Motley Fool
July 11, 2011
Seth Jayson |
Why OraSure Technologies May Be About to Take Off Is the current inventory situation at OraSure Technologies out of line? To figure that out, start by comparing the company's figures to those from peers and competitors. |
The Motley Fool
July 11, 2011 |
Cubist Pharmaceuticals Earnings Preview Cubist Pharmaceuticals will unveil its latest earnings on Thursday. |
The Motley Fool
July 8, 2011
Brian Orelli |
Half a Breakup Is Better Than No Breakup at All Pfizer keeps two divisions and puts two on the chopping block. |
The Motley Fool
July 8, 2011
Rich Smith |
What's All the Fuss About Zalicus? Stock's up on an Oppy upgrade. |
The Motley Fool
July 8, 2011
Brian Orelli |
Let's Just Hope For No More FDA Surprises Despite the government's worries, Bydureon doesn't cause heart issues. |
The Motley Fool
July 8, 2011
Seth Jayson |
Here's Why Vascular Solutions' Latest Report Might Worry You On a trailing-12-month basis, finished goods inventory was the fastest-growing segment, up 32.5%. That can be a warning sign. |
| <Older 7621-7630 Newer> Return to current articles. |
